Quick Answer
Grace Therapeutics, Inc. reported Stockholders Equity of $66.61 million for the year ending 2025.
- Grace Therapeutics, Inc. showed an increase of +7.9% in Stockholders Equity from 2024 to 2025.
- This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $3.28 million | Q3 2019: -$759.0 thousand | Q4 2019: -$4.29 million | Q2 2020: $11.04 million | Q3 2020: $8.87 million | Q4 2020: $25.72 million | Q2 2021: $53.46 million | Q3 2021: $114.20 million | Q4 2021: $111.06 million | Q2 2022: $104.40 million | Q3 2022: $100.16 million | Q4 2022: $96.72 million | Q2 2023: $64.01 million | Q3 2023: $66.75 million | Q4 2023: $64.68 million | Q1 2024: $61.74 million | Q2 2024: $59.36 million | Q3 2024: $56.13 million | Q4 2024: $52.14 million | Q1 2025: $66.61 million | Q2 2025: $63.55 million | Q3 2025: $62.82 million | Q4 2025: $64.89 million.
- Over the full 8 years of available data (2018 to 2025), Grace Therapeutics, Inc.'s Stockholders Equity has grown by 826.0%.
- Historical annual values: Fiscal year 2025: $66.61 million | Fiscal year 2024: $61.74 million | Fiscal year 2023: $67.96 million | Fiscal year 2022: $108.27 million | Fiscal year 2021: $55.66 million | Fiscal year 2020: $12.99 million | Fiscal year 2019: $11.05 million | Fiscal year 2018: $7.19 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: